Founded by experienced physician innovators and technology entrepreneurs, Firefly marries sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value. The platform enables people to make smart choices about their health, while allowing clinicians to provide unparalleled, consistent and proactive care.
Insilico Medicine
Insilico specializes in artificial intelligence for drug discovery, biomarker development and aging research.
Singular Genomics
Singular Genomics (NASDAQ: OMIC) is developing a new next generation sequencing platform.
BioPalette
BioPalette is a life science start up formed out of Kobe University developing base editing technology for a range of applications.
Structure Therapeutics
Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.
Verve Therapeutics
Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve was acquired by Eli Lilly in 2025.
Arvelle Therapeutics
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.
Nocion Therapeutics
Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including cough, pain, and itch.
Embark
Embark Veterinary, Inc. launched in 2015 with a mission to end preventable disease in dogs. An Embark Dog DNA Test enables pet owners to learn about their dog’s breed, ancestry, health, and what diseases may be in the future – all with a simple cheek swab. By using 100 times more genetic information than any other test available, the company offers the most accurate results on the market. Embark was started by two brothers, Adam and Ryan Boyko, who have a passion for scientific research and a lifelong love of dogs. Embark is an official research partner with Cornell University College of Veterinary Medicine.
Caplin Point Laboratories
Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited.